CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 154 enrolled
Drug / intervention
BioThrax +1 morebiological
Likely dose
BioThrax 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01753115
NCT01753115Phase 2Completed
CompareCT.gov

A Study of The Effects of Co-Administering Ciprofloxacin and BioThrax on the Pharmacokinetics of Ciprofloxacin in Healthy Adults

Emergent BioSolutions·interventional·Posted Dec 20, 2012·Updated Jun 15, 2025

In Brief

A Phase 2 clinical trial evaluating BioThrax and Ciprofloxacin for Anthrax. Completed, enrolled 154 participants across 3 sites.

Detailed Summary

The purpose of this clinical trial is to determine whether there is any effect on the antibiotic, ciprofloxacin when taken before and after administration of a 3-dose series of BioThrax® (Anthrax Vaccine Adsorbed or AVA). This study will be conducted in the United States (US) in 154 healthy male and female volunteer subjects ages 18 to 45. The duration of study participation for each subject will be approximately 76 days (approximately 2.5 months)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnthrax
CountriesUnited States
CollaboratorsDepartment of Health and Human Services

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedDec 20, 2012
Enrollment StartDec 1, 2012
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 13.5 years ago

Interventions

BioThraxbiological

route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule

Ciprofloxacindrug

500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48).